cefatrizine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 529 51627-14-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefatrizine
  • cefaperos
  • cephatrizin
  • cephatrizine
  • cepticol
Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.
  • Molecular weight: 462.50
  • Formula: C18H18N6O5S2
  • CLOGP: -2.88
  • LIPINSKI: 1
  • HAC: 11
  • HDO: 5
  • TPSA: 174.53
  • ALOGS: -3.49
  • ROTB: 7

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 30.89 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 66 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.22 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.20 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.459 Moderate 0.67
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.745 Moderate 0.67
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.359 10^-6 cm/s Moderate 0.67
dh-clint Dog hepatocyte intrinsic clearance 1.030 uL/min/10^6 cells Moderate 0.67
dppb Dog plasma protein binding (% unbound) 51.730 % Moderate 0.67
fcs-ppb Fetal calf serum protein binding (% unbound) 35.830 % Moderate 0.67
herg hERG pIC50 4.678 pIC50 Moderate 0.67
hh-clint Human hepatocyte intrinsic clearance 2.449 uL/min/10^6 cells Moderate 0.67
hlm-clint Human liver microsomal intrinsic clearance 4.808 uL/min/mg protein Moderate 0.67
hppb Human plasma protein binding (% unbound) 28.470 % Moderate 0.67
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TTK 36
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,TEK,TGFBR1,TTK 18
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.348 Moderate 0.67
mh-clint Mouse hepatocyte intrinsic clearance 5.610 Moderate 0.67
mppb Mouse plasma protein binding (% unbound) 52.760 Moderate 0.67
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.650 Moderate 0.67
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 28.050 % Moderate 0.67
rh-clint Rat hepatocyte intrinsic clearance 2.317 uL/min/10^6 cells Moderate 0.67
rh-fuinc Rat hepatocyte fraction unbound in incubation 84.030 % Moderate 0.67
rppb Rat plasma protein binding (% unbound) 24.030 % Moderate 0.67
solubility-dd Solubility at pH 7.4 in DMSO 895.365 uM Moderate 0.67

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:131734 EC 2.7.11.20 (elongation factor 2 kinase) inhibitor

Related Drugs by ATC class:

J01DB First-generation cephalosporins 11 drugs
cefacetrilecefadroxilcefalexincefaloridinecefalotincefapirincefazedonecefazolincefradinecefroxadineceftezole

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.1 acidic
pKa2 6.75 acidic
pKa3 9.72 acidic
pKa4 13.53 acidic
pKa5 7.63 Basic
pKa6 0.02 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000166880 NUI
D02406 KEGG_DRUG
2179 RXNORM
C0007545 UMLSCUI
CHEBI:131730 CHEBI
CHEMBL1095284 ChEMBL_ID
D002436 MESH_DESCRIPTOR_UI
DB13266 DRUGBANK_ID
12204 IUPHAR_LIGAND_ID
3839 INN_ID
8P4W949T8K UNII
6410758 PUBCHEM_CID
50020121000188105 SNOMEDCT_US
96056009 SNOMEDCT_US
004202 NDDF
8P4W949T8K INXIGHT DRUGS

Pharmaceutical products:

None